Presented by
IVBM Event Coverage
Operationalizing Seamless Care Between Community and Academic Centers: Turab Mohammed, MD
Learn how CRS and ICANS present in patients undergoing immunotherapy and what clinicians should know about recognizing and managing these toxicities.
A Multilevel Strategy for Diversity in Clinical Trials: Tina Bhatnagar, DO
Tina Bhatnagar, DO, speaks to the importance of diversity in clinical trials and the need to remove barriers, enroll underrepresented backgrounds, and reflect real-world health conditions.
Closing Breast Cancer Screening Gaps Through Community Outreach, Credible Messaging: Kathrin Dvir, MD, MSc
Kathrin Dvir, MD, MSc, concludes by highlighting the importance of outreach, education, and trusted messaging to improve breast cancer screening adherence.
Ensuring Access to Advanced Multiple Myeloma Treatments Amid Delivery Challenges: Ameet Patel, MD
Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.
Balancing Safety, Logistics in Multiple Myeloma Treatment Settings: Ameet Patel, MD
Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.
Adapting CAR-T and Cell Therapies for Community Oncology: Biagio Ricciuti, MD
Ricciuti explains why advanced adoptive cell therapies require major infrastructure, toxicity management, and strong academic–community collaboration.
Access Barriers Limit Community Adoption of Novel Therapies: Biagio Ricciuti, MD
Biagio Ricciuti, MD, discusses how access challenges and toxicity concerns slow the rollout of new T-cell engager therapies from academic centers into community oncology.
Bringing Academic Oncology Best Practices to Community Care: Anasuya Gunturi, MD, PhD
Anasuya Gunturi, MD, PhD, explains how academic–community partnerships help deliver complex oncology services closer to home.
Oncology Pharmacy Is Critical to Modern Cancer Care: Kenneth Komorny, PharmD, BCPS
As more oral cancer therapies become available, medically integrated dispensing models are increasingly vital, says Kenneth Komorny, PharmD, BCPS.
Bridging the Academic-Community Gap in Cancer Care: Andrew Yee, MD
Andrew Yee, MD, explains how academic centers can share practical oncology best practices that community hospitals can implement sustainably.
Debunking Myths to Boost Clinical Trial Enrollment Diversity: Susan Vadaparampil, PhD, MPH
Susan Vadaparampil, PhD, MPH, explains that aligning clinical trials with community needs can improve enrollment diversity.
Academic–Community Oncology Partnerships Improve Access: Anasuya Gunturi, MD, PhD
Community-academic collaboration can reduce access burdens and strengthen continuity of care, says Anasuya Gunturi, MD, PhD.
High-Performing MID Programs Integrate Pharmacists Into Oncology Care Teams: Q&A With Osama Abdelghany, PharmD
Osama Abdelghany, PharmD, explains how medically integrated dispensing improves oncology workflows, patient access, and outcomes through EMR-driven care.
MID Models Foster Patient Trust, Boost Adherence: Kenneth Komorny, PharmD, BCPS
Medically integrated dispensing (MID) models help build patient trust in pharmacists, which can help improve adherence, explains Kenneth Komorny, PharmD, BCPS.
Community Collaboration Key to Inclusive Clinical Trial Design: Amir Fathi, MD
Community partnerships and trial design reforms can reduce travel barriers and improve underserved patient representation, said Amir Fathi, MD.
Overcoming Mistrust in Clinical Trial Enrollment Through Community Resources: Susan Vadaparampil, PhD, MPH
Patient navigators, community health workers, and/or peer advocates serve as trusted community resources for patients, Susan Vadaparampil, PhD, MPH, says.
Catchment Areas Shape Diversity and Access in Oncology Trials: Amir Fathi, MD
Catchment areas, access, and partnerships influence diversity in oncology trials, Amir Fathi, MD, explains at a Boston IVBM panel.
Medically Integrated Dispensing Strengthens Oncology Care Through Real-Time EMR Access: Sam Abdelghany, PharmD, BCOP, MHA
Medically integrated dispensing improves oncology treatment coordination through EMR-based care, but payer restrictions remain a key barrier.
Medically Integrated Dispensing Helps Prevent Oncology Care Fragmentation: Katherine Tobon, PharmD, BCOP
Medically integrated dispensing is well-positioned to support value-based oncology care models and closer patient follow-up and monitoring, says Katherine Tobon, PharmD, BCOP.
MID Models Reduce Adverse Events, Lower Costs in Oncology: Kenneth Komorny, PharmD, BCPS
MID in oncology also enhances treatment adherence and improves patient outcomes, according to Kenneth Komorny, PharmD, BCPS.
Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP
Medically integrated dispensing (MID) improves monitoring and supports value-based care, but startup costs and payer barriers remain, notes Katherine Tobon, PharmD, BCOP.
Linking Community Screening Programs to Cancer Centers Boosts Trial Diversity: Susan Vadaparampil, PhD, MPH
Susan Vadaparampil, PhD, MPH, highlights disparities in cancer outcomes and trial enrollment but underscores that linking community screening programs with cancer centers may help.
New Multiple Myeloma Therapies Offer Hope for Potential Cure: Ameet Patel, MD
Targeted therapies, bispecifics, and CAR T-cell therapies are giving patients with multiple myeloma hope for long-term remission or a potential cure.
Pharmacy Innovations That Improve Care Quality, Cut Costs: A Q&A With Jose Guzman Garcia, PharmD, MHA, BCCCP
Jose Guzman Garcia, PharmD, MHA, BCCCP, discusses key pharmacy initiatives at UC Davis Health.
AI Can Help Community and Academic Oncology Practices: Tina Bhatnagar, DO
Bhavana (Tina) Bhatnagar, DO, discusses the transformative role of AI in enhancing patient care at West Virginia University Cancer Institute.
Invest in Human Capital to Improve Breast Cancer Care Delays: Adam Brufsky, MD, PhD
Delays in breast cancer diagnosis and treatment highlight the need for improved human capital investment in health care systems, explains Adam Brufsky, MD, PhD.
Team-Based Cancer Care Vital in the Community: Danielle Roman, PharmD, BCOP
Danielle Roman, PharmD, BCOP, explains why a collaborative, team-based approach is essential to solving resource challenges in community cancer care.
Digital Innovation and New Drugs Converge to Transform CRM Care
Academic and clinical experts convened in New Haven, Connecticut, on October 30, 2025, to discuss the potential of coordinated care and prevention to manage cardio-renal-metabolic (CRM) disease.
Transforming Population Health for Diabetes and Kidney Disease via Systems of Excellence
Clinicians and health system leaders met in Cleveland, Ohio, on October 23, 2025, to share improvements to value-based care in diabetes and chronic kidney disease.
Expanding Precision Care for Alzheimer Disease, Multiple Sclerosis
Clinicians and health system leaders met in Portland, Oregon, on October 21, 2025, to discuss the evolving options for treating Alzheimer disease and multiple sclerosis.
